Eagle Asset Management Inc Biogen Inc. Transaction History

Eagle Asset Management Inc

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2020 Aug 12, 2020	SELL	$258.66 - $342.55 $1.28 Million - $1.69 Million	-4,942 Closed	0 $0
Q1 2020 May 11, 2020	SELL	$268.85 - $341.04 $41,940 - $53,202	-156 Reduced 3.06%	4,942 $1.56 Million
Q4 2019 Feb 07, 2020	SELL	$220.06 - $304.07 $1.16 Million - $1.61 Million	-5,279 Reduced 50.87%	5,098 $1.51 Million
Q3 2019 Nov 04, 2019	BUY	$217.44 - $243.88 $2.26 Million - $2.53 Million	10,377 New	10,377 $2.42 Million
Q1 2019 May 01, 2019	SELL	$216.71 - $338.96 $155,814 - $243,712	-719 Closed	0 $0
Q4 2018 Feb 11, 2019	BUY	$278.5 - $352.75 $36,483 - $46,210	131 Added 22.28%	719 $216,000
Q3 2018 Nov 08, 2018	BUY	$293.51 - $383.83 $172,583 - $225,692	588 New	588 $207,000

1,037

126M

1.13M

1.43M

Ticker BIIB
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 144,000,992
Market Cap $22.7B
Description
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...

Get notified when there are updates to the investment portfolio of Eagle Asset Management Inc, based on Form 13F filings with the SEC.

Stay updated on Eagle Asset Management Inc with notifications on news.